Über uns

Apogenix develops innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signaling pathways, thereby restoring the anti-tumor immune response in cancer patients and reducing lymphopenia and inflammatory cell death in patients with viral infections.

The company's lead immunotherapy candidate asunercept is in clinical development for solid tumors and hemato-oncological indications, with a pivotal phase II/III study planned for glioblastoma, the most frequent and aggressive brain tumor. Given the urgent need for COVID-19 treatments and based on a strong scientific rationale of using asunercept to block CD95L-mediated epithelial lung damage, Apogenix is currently evaluating asunercept in a phase II trial in COVID-19 patients in Spain and Russia.

In recurrent glioblastoma, asunercept has demonstrated significant improvements in progression-free survival and quality of life as well as a positive trend in overall survival in a controlled phase II proof of concept trial.

Asuncerpt has also been evaluated in a phase I trial for the treatment of myelodysplastic syndromes (MDS), a stem cell disorder that can lead to severe anemia. Forty percent of patients showed a marked reduction in transfusion frequency during the duration of the trial.

The Apogenix team has further developed a proprietary technology platform for the construction of novel receptor agonists that target different TNFSF-dependent signaling pathways, which play a crucial role in the regulation of the immune response. These TNFSF receptor agonists overcome the structural limitations of other biologics targeting TNFSF pathways, such as antibodies. They stimulate and enhance the anti-tumor immune response and have the potential for broad application in oncology.